The Multiple Sclerosis International Federation (MSIF) states that 2.8 million people around the globe were living with multiple sclerosis in 2020, and this autoimmune disease affects around 1 in 3,000 people worldwide. Further, the American Lung Association estimates that approximately 200,000 new cases of sarcoidosis are recorded in the U.S. each year. Additionally, the National Organization for Rare Disorders states that 1 in 10,000 individuals around the world are affected by systemic scleroderma, and this autoimmune disorder is highly prevalent among the Australian and North American populations.
Thus, the increasing prevalence of autoimmune disorders is expected to drive the autoimmune disease diagnostics market at a CAGR of 8.5% during the forecast period 2020–2030. According to P&S Intelligence, the market was valued at $4,086.2 million in 2019, and it will generate $10,012.9 million revenue by 2030. The market growth is also facilitated by the rising public awareness regarding such diseases and the increasing number of awareness programs being organized by public and private organizations to impart knowledge about such disorders.
In recent years, several researchers have discovered new biological markers or biomarkers to diagnose autoimmune diseases. For example, in August 2019, researchers at the University of Alberta discovered a new biological marker to identify the existence of myasthenia gravis, a rare autoimmune disease. This biomarker can also be utilized for formulating new personalized treatment procedures and predicting the course of the disease. Scientists around the world are also discovering biomarkers to detect multiple sclerosis, rheumatoid arthritis (RA), sarcoidosis, scleroderma, systemic lupus erythematosus (SLE), and sjögren’s syndrome.
The product segment of the autoimmune disease diagnostics market is bifurcated into instruments, and consumables and assay kits. Of these, the consumables and assay kits category generated a higher revenue during the historical period (2014–2019), and it is expected to retain its dominance in the forecast years as well. This can be ascribed to the surging incidence of autoimmune diseases and the rising number of research activities to identify the cause of such diseases.
These autoimmune disease diagnostic products are used in academic institutes and research centers, hospitals, and diagnosing centers in autoantibodies and immunology, cytokine, flow cytometry, human leukocyte antigen (HLA), inflammatory marker, and routine laboratory tests. Currently, hospitals are the largest user of such products, owing to the improving healthcare infrastructure, the rising prevalence of chronic autoimmune disorders, the soaring number of awareness programs and campaigns being conducted by public and private organizations, and the increasing deployment of technologically advanced medical devices by these healthcare facilities.
Globally, the North American autoimmune disease diagnostics market generated the highest revenue during the historical period, on account of the mounting healthcare expenditure, soaring aging population, and increasing cases of autoimmune diseases in the region. Additionally, the presence of leading market players also contributes to the regional market growth. Whereas, the Asia-Pacific market is expected to display the fastest growth throughout the forecast period, owing to the booming elderly population and mounting public awareness regarding autoimmune diseases in regional countries.
Therefore, the surging burden of autoimmune diseases and the growing public awareness about such disorders will facilitate the adoption of autoimmune disease diagnostic products, globally.